Manages moderately severe acute pain. ANDA 210616, held by Chartwell RX. Ketorolac Tromethamine.
As of Nov 21, 2026, ANDA 210616 (Ketorolac Tromethamine), held by Chartwell RX, was first approved by FDA on Aug 16, 2018, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. Acute Pain in Adult Patients Ketorolac tromethamine tablets are indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with ketorolac tromethamine-IV or IM and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 16, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ketorolac Tromethamine10MG · tablet;oral | Ketorolac Tromethamine | Rx |
| Nov 21, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 28, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 16, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters